SCHEMBL14033741

SCHEMBL14033741

OC(c1ccc(Cl)cc1)c1cnc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 1/20 0.49
CYP2D6 P10635 4/20 0.43
CYP3A4 P08684 3/20 0.43
SLC6A2 P23975 3/20 0.43
SLC6A4 P31645 3/20 0.43
SLC6A3 Q01959 3/20 0.43
CNR1 P21554 2/20 0.42
CNR2 P34972 2/20 0.42
CYP1A2 P05177 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
POLB P06746 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MGAM O43451 1/20 0.41
GAA P10253 1/20 0.41
TMPRSS4 Q9NRS4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14033830 0.83 NPC1 (0.46) CYP2D6CNR1CNR2CYP1A2MEN1
SCHEMBL22229535 0.81 MGAM (0.42) CHEK2CYP2D6CYP3A4SLC6A2SLC6A4
SCHEMBL22229487 0.80 CHEK2 (0.41) CHEK2CYP2D6CYP3A4SLC6A2SLC6A4
SCHEMBL372349 0.78 CYP1A2 (0.52) CHEK2CYP1A2HPGDRAB9AMGAM
SCHEMBL22229537 0.77 TRPM8 (0.41) CHEK2CYP2D6CYP3A4SLC6A2SLC6A4
SCHEMBL22229492 0.77 EGFR (0.39) CHEK2CYP2D6CYP3A4SLC6A2SLC6A4
SCHEMBL22229517 0.77 NQO1 (0.39) CHEK2CYP2D6CYP3A4SLC6A2SLC6A4
SCHEMBL14033733 0.76 UGT2B7 (0.55) CHEK2CYP2D6CYP3A4SLC6A2SLC6A4
SCHEMBL7245487 0.76 CYP1A2 (0.43) CHEK2CYP1A2HPGDRAB9AMGAM
SCHEMBL18812958 0.76 CHEK2 (0.42) CHEK2CYP1A2NPC1RAB9AMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed